Top

Indian Journal of Hematology and Blood Transfusion

Published in:

01-09-2014 | Review Article

Blood Substitutes: Possibilities with Nanotechnology

Authors: Feroz Alam, Neha Yadav, Murad Ahmad, Mariyam Shadan

Published in: Indian Journal of Hematology and Blood Transfusion | Issue 3/2014

Abstract

Nanotechnology deals with molecules in the nanometer (10⁻⁹) range and is currently being used successfully in the field of medicine. Nanotechnology has important implications in nearly all the branches of medicine and it has all the capabilities to revolutionize the vast field of medicine in future. Nanotechnological advancements have been used for the preparation of artificial hemoglobin. It is formed by assembling the hemoglobin molecules into a soluble complex. A recent approach includes the assembling of this artificial hemoglobin with enzymes such as catalase and superoxide dismutase into a nano-complex. This complex acts as an oxygen carrier as well as an antioxidant in conditions with ischemia–reperfusion injuries.

Aggarwal S, Sharma V (2012) Attitudes and problems related to voluntary blood donation in India: a short communication. Ann Trop Med Public Health 5:50–52

Blood safety and clinical technology. Available at-http://www.searo.who.int/en/section10/section17/section1976.htm

Chaitanya kumar IS, Yashoverdhan (2011) Efforts to meet the challenges of 100 % voluntary blood donation. Asian J Transfus Sci 5:68–69CrossRef

Based on WHO Global Database on Blood Safety (GDBS) 2008, with responses received from 164 countries, covering 92 % of the world’s population. Available at http://www.who.int/bloodsafety/global_database/GDBS_Summary_Report_2011.pdf

Geyer RP, Monroe RG, Taylor K (1968) Survival of rats having red cells totally replaced with emulsified fluorocarbon. Federation Proc 27:384–390

Sloviter H, Kamimoto T (1967) Erythrocyte substitute for perfusion of brain. Nature 216:458–460PubMedCrossRef

Keipert PE (1998) Perfluorochemical emulsions: future alternatives to transfusion. Blood Subst Princ Meth Prod Clin Trials 2:127–156

Spahn DR, Leone BJ, Reves JG, Pasch T (1994) Cardiovascular and coronary physiology of acute isovolemic hemodilution: a review of nonoxygen-carrying and oxygen-carrying solutions. Anesth Analg 78:1000–1021PubMedCrossRef

Riess JG (1992) Overview of progress in the fluorocarbon approach to in vivo oxygen delivery. Biomater Artif Cells Immobil Biotechnol 20:183–202

10.

Lowe KC (1999) Perfluorinated blood substitutes and artificial oxygen carriers. Blood Rev 13:171–184PubMedCrossRef

11.

Riess JG, Krafft MP (1998) Fluorinated materials for in vivo oxygen transport (blood substitutes), diagnosis and drug delivery. Biomaterials 19:1529–1539PubMedCrossRef

12.

Mattrey RF (1994) The potential use of Perflourochemicals (PFC’s) in diagnostic imaging. Artif cells, Blood Substit Immobil Biotechnol 22:295–313CrossRef

13.

Antonini E, Brunori M (1971) “Kinetics of the reactions of hemoglobin and myoglobin with ligands” Chapter 8 in: hemoglobin and myoglobin in their reactions with ligands. Frontiers of Biol, North-Holland Publishing Company 21:189–217

14.

Ackers GK, Johnson ML (1981) Linked functions in allosteric proteins. J Mol Bio 147:559–582CrossRef

15.

Benesch R, Benesch RE (1969) Intracellular organic phosphates as regulators of oxygen release by haemoglobin. Nature 221:618–622PubMedCrossRef

16.

Antonini E, Condò SG, Giardina B, Ioppolo C, Bertollini A (1982) The effect of pH and d-glycerate 2,3 bisphosphate on the O₂ equilibrium of normal and SH(_93)-modified human haemoglobin. Eur J Biochem 121:325–328PubMedCrossRef

17.

Oto B. Respiration and hemoglobin, EMS basics. Available at: http://emsbasics.com/2011/08/03/respiration-and-hemoglobin/

18.

Kresie L (2001) Artificial blood: an update on current red cell and platelet substitutes. BUMC Proc 14:158–161

19.

Winslow RM (2006) Current status of oxygen carriers (‘blood substitutes’). Vox Sang 91:102–110PubMedCrossRef

20.

Carson JL, Noveck H, Berlin JA, Gould SA (2002) Mortality and morbidity in patients with very low postoperative Hb levels who decline blood transfusion. Transfusion 42:812–818PubMedCrossRef

21.

Chang TMS (1964) Semipermeable microcapsules. Science 146:524PubMedCrossRef

22.

Chang TMS. Artificial cells. Monograph. Charles C Thomas, Springfield, IL, 1972. (full text available at www.artcell.mcgill.ca)

23.

Chang TMS (1971) Stabilisation of enzymes by microencapsulation with a concentrated protein solution or by microencapsulation followed by cross-linking with glutaraldehyde. Biochem Biophys Res Common 44:1531–1536CrossRef

24.

Chang TMS (2007) Monograph on “ARTIFICIAL CELLS: biotechnology,nanotechnology, blood substitutes, regenerative medicine, bioencapsulation,cell/stem cell therapy”. World Science Publisher, Singapore, p 452. Available at:http://www.medicine.mcgill.ca/artcell/2007%20ebook%20artcell%20web.pdf

25.

Chang TMS. Blood substitutes: principles, methods, products and clinical trials. Vol.1 Basel Karger,1997. (full text and updates available at www.artcell.mcgill.ca)

26.

Gould SA, Moore EE, Hoyt DB, Ness PM, Norris EJ, Carson JL et al (2002) The life-sustaining capacity of human polymerized Hb when red cells might be unavailable. J Am Coll Surg 195:445–452PubMedCrossRef

27.

Pearce LB, Gawryl MS, Rentko VT, Moon-Massat PF, Rausch CW (2006) HBOC-201 (Hb Glutamer-250 (Bovine), Hemopure): clinical studies. In: Winslow R (ed) Blood substitutes. Academic Press, San Diego, pp 437–450CrossRef

28.

D’Agnillo F, Chang TMS (1998) PolyHb-superoxide dismutase. Catalase as a blood substitute with antioxidant properties. Nat Biotechnol 16:667–671PubMedCrossRef

29.

Chang TMS (1985) Artificial cells with regenerating multienzyme systems. Meth Enzymol 112:195–203PubMedCrossRef

30.

Gu KF, Chang TMS (1988) Conversion of ammonia or urea into l-leucine, l-valine and l-isoleucine using artificial cell immobilising multienzyme system and dextran-NADH+. I. Glucose dehydrogenase for cofactor recycling. J Am Soc Artif Intern Organs 11:24–28

31.

Chang TMS, Powanda D, Yu WP (2003) Ultrathin polyethylene-glycolpolylactide copolymer membrane nanocapsules containing polymerized Hb and enzymes as nano-dimension red blood cell substitutes. Artif Cells Blood Substit Biotechnol 3:231–248CrossRef

32.

Djordjevich L, Miller IF (1980) Synthetic erythrocytes from lipid encapsulated Hb. Exp Hematol 8:584PubMed

33.

Philips WT, Klpper RW, Awasthi VD, Rudolph AS, Cliff R, Kwasiborski VV et al (1999) Polyethylene glyco-modified liposome-encapsulated Hb: a long circulating red cell substitute. J Pharm Exp Therapeutics 288:665–670

34.

Chang TMS (1976) Biodegradable semipermeable microcapsules containing enzymes, hormones, vaccines, and other biologicals. J Bioengineering 1:25–32

35.

Yu WP, Chang TMS (1994) Submicron biodegradable polymer membrane Hb nanocapsules as potential blood substitutes: a preliminary report. Artif Cells Blood Substit Immobil Biotechnol 22:889–894PubMedCrossRef

36.

Yu WP, Chang TMS (1996) Submicron biodegradable polymer membrane Hb nanocapsules as potential blood substitutes. Artif Cells Blood Substit Immobil Biotechnol 24:169–184PubMedCrossRef

37.

Chang TMS, Yu WP, Yu WP (1998) Nanoencapsulation of Hb and RBC enzymes based on nanotechnology and biodegradable polymer. In: Chang TMS (ed) Blood substitutes: principles, methods, products and clinical trials, vol 2. Karger, Basel, pp 216–231

Title: Blood Substitutes: Possibilities with Nanotechnology
Authors: Feroz Alam
Neha Yadav
Murad Ahmad
Mariyam Shadan
Publication date: 01-09-2014
Publisher: Springer India
Published in: Indian Journal of Hematology and Blood Transfusion / Issue 3/2014
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI: https://doi.org/10.1007/s12288-013-0309-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2014

Prevalence of Bombay Group Blood in Southern Bengal Population

Hairy Cell Leukemia: Clinicopathological and Immunophenotypic Study

Rare Case of Acquired Haemophilia and Lupus Anticoagulant

Platelet Satellitism: A Rare, Interesting, In Vitro Phenomenon

Platelet Storage Media Change the Expression Characteristics of the Platelet-Derived Microparticles

Ocular Adnexal Lymphomas: Report of 2 Cases of Mantle Cell Lymphomas and Short Review of Literature

Keynote webinar | Spotlight on antibody–drug conjugates in cancer